ACADL: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
CSV import
 
Line 24: Line 24:
{{medicine-stub}}
{{medicine-stub}}
{{No image}}
{{No image}}
__NOINDEX__

Latest revision as of 03:03, 17 March 2025

ACADL or Acyl-CoA Dehydrogenase, Long Chain is an enzyme that in humans is encoded by the ACADL gene. It is involved in the breakdown of long-chain fatty acids, a process that provides energy for the body. Mutations in this gene can lead to a variety of metabolic disorders, including lipid metabolism disorders and fatty acid oxidation disorders.

Function[edit]

The ACADL enzyme is part of a family of enzymes known as Acyl-CoA dehydrogenases. These enzymes catalyze the dehydrogenation of acyl-CoA derivatives in the metabolism of fatty acids and some amino acids. The enzyme encoded by this gene uses flavin adenine dinucleotide (FAD) as a cofactor to catalyze the initial step of the mitochondrial fatty acid beta-oxidation pathway.

Clinical significance[edit]

Mutations in the ACADL gene can lead to a deficiency in the ACADL enzyme, a condition known as ACADL deficiency or long-chain acyl-CoA dehydrogenase deficiency (LCAD deficiency). This is a rare inherited disorder that prevents the body from converting certain fats into energy. Symptoms can include hypoglycemia, muscle weakness, and cardiomyopathy.

Diagnosis and Treatment[edit]

Diagnosis of ACADL deficiency is typically made through a combination of clinical examination, biochemical testing, and molecular genetic testing. Treatment typically involves dietary management to avoid long periods of fasting, and in some cases, supplementation with medium-chain triglycerides.

See also[edit]


Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!